Kathy J. Helzlsouer, MD, MHS, has been named Associate Director and Chief Medical Officer in NCI’s Division of Cancer Control and Population Sciences. She will direct the Epidemiology and Genomics Research Program, which includes the Office of the Associate Director, Clinical and Translational Epidemiology Branch, Environmental Epidemiology Branch, Genomic Epidemiology Branch, Methods and Technologies Branch, and Risk Factor Assessment Branch.
Valuable Blend of Skills
Robert Croyle, PhD, Director of the Division, said, “Dr. Helzlsouer is a highly accomplished epidemiologist and clinician with a broad vision of cancer epidemiology, prevention, and control. She brings a valuable blend of medical, scientific, and leadership skills, which will be a strong asset for NCI and the Division of Cancer Control and Population Sciences.”
Prior to joining NCI, she was a Professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health and, since 2004, she directed The Prevention & Research Center, which she established at Mercy Medical Center in Baltimore. Dr. Helzlsouer led a team of health-care specialists in cancer risk assessments, clinical research, and support programs for cancer patients and their families.
Dr. Helzlsouer also is an associate editor of the Journal of the National Cancer Institute and a member of NCI’s PDQ® Screening and Prevention Editorial Board. Her research interests are focused in cancer etiology and prevention, cancer survivorship, and clinical and translational research. Dr. Helzlsouer is a recipient of the Martin D. Abeloff Award for Excellence in Public Health and Cancer Control for her service on the Maryland State Council on Cancer Control.
Dr. Helzlsouer completed her medical degree at the University of Pittsburgh School of Medicine, her internal medicine residency at the University of Virginia, and her medical oncology fellowship at Johns Hopkins University. She also earned a Master of Health Science at Johns Hopkins University. Dr. Helzlsouer is board certified in medical oncology. ■